Sep 06, 2016 7:05am EDT Matinas BioPharma to Present at the 18th Annual Rodman & Renshaw Global Investment Conference in New York City on September 13, 2016
Jul 13, 2016 7:00am EDT Matinas BioPharma Announces Presentation of Cryptococcal Meningitis Preclinical Data of MAT2203 at AIDS-Associated Mycosis Meeting 2016
Jun 22, 2016 7:05am EDT Matinas BioPharma Receives Issuance of Key U.S. Patent for Novel Lipid-Crystal Nano-Particle Cochleate Formulation Technology
Jun 20, 2016 7:35am EDT Matinas BioPharma Presents Preclinical Data of MAT2501 at ASM Microbe/ICAAC 2016
Jun 08, 2016 7:00am EDT Matinas BioPharma Announces Acceptance of Abstract on Efficacy and Tolerability of Encochleated Ibuprofen in Rat Carrageenan-Induced Paw Inflammation Model for EULAR 2016
Mar 31, 2016 7:05am EDT Matinas BioPharma Reports 2015 Financial Results and Provides Business Update
Mar 07, 2016 7:05am EST Matinas BioPharma Granted U.S. Orphan Drug Designation for MAT2501 for Treatment of Non-Tuberculous Mycobacteria Infections
Feb 10, 2016 8:05am EST Matinas BioPharma Receives Notice of Allowance of U.S. Patent for Novel Lipid-Crystal Nano-Particle Cochleate Formulation Technology
Feb 08, 2016 7:05am EST Matinas BioPharma Commences Patient Enrollment in NIH-Sponsored Phase 2a Study With MAT2203 - Oral Encochleated Amphotericin B
